Vertex Pharmaceuticals Incorporated
VRTX
$401.08
$0.920.23%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 8.96% | 6.00% | 5.33% | 32.99% | 41.84% |
| Total Depreciation and Amortization | 14.30% | 11.83% | 11.97% | 13.94% | 18.07% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -99.34% | 324.01% | -40.23% | -39.70% | 13.45% |
| Change in Net Operating Assets | -177.96% | -14.83% | -5.05% | 432.36% | 423.95% |
| Cash from Operations | -14.35% | 8.27% | 1.24% | 52.07% | 56.23% |
| Capital Expenditure | 2.10% | 24.47% | 18.00% | 19.54% | 12.89% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 100.00% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,738.61% | -1,768.20% | -2,624.30% | -1,707.12% | 269.50% |
| Cash from Investing | -878.42% | -229.73% | -683.60% | -562.37% | 5.81% |
| Total Debt Issued | -48.57% | -65.00% | -68.18% | -81.58% | -84.51% |
| Total Debt Repaid | 47.49% | 50.51% | -62.67% | -74.42% | -81.91% |
| Issuance of Common Stock | -27.75% | -17.47% | 9.82% | 38.88% | 82.65% |
| Repurchase of Common Stock | -280.06% | 6.80% | 66.95% | 69.27% | 88.98% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -76.32% | -88.89% | -103.51% | -100.00% |
| Cash from Financing | -730.43% | 9.43% | 71.42% | 74.68% | 95.42% |
| Foreign Exchange rate Adjustments | 192.12% | 153.81% | 154.42% | 26.14% | -117.91% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -103.76% | -33.04% | -44.96% | 31.02% | 357.58% |
